Firefly Neuroscience (NASDAQ:AIFF) Announces Earnings Results

Firefly Neuroscience (NASDAQ:AIFF) posted its quarterly earnings results on Monday. The company reported ($0.10) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $0.51 million for the quarter. Firefly Neuroscience had a negative return on equity of 94.68% and a negative net margin of 565.40%.

Firefly Neuroscience Stock Up 2.4%

Shares of NASDAQ:AIFF traded up $0.03 during trading on Tuesday, reaching $1.22. 8,327 shares of the company’s stock traded hands, compared to its average volume of 4,396,667. Firefly Neuroscience has a fifty-two week low of $0.62 and a fifty-two week high of $3.63. The firm has a market cap of $19.03 million, a PE ratio of -1.90 and a beta of 0.57. The company has a 50-day simple moving average of $1.29 and a 200-day simple moving average of $1.46.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on AIFF. Wall Street Zen raised Firefly Neuroscience from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings upgraded Firefly Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, May 19th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Hedge Funds Weigh In On Firefly Neuroscience

Large investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its position in shares of Firefly Neuroscience by 92.9% during the 2nd quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock valued at $341,000 after buying an additional 58,067 shares in the last quarter. Vanguard Group Inc. raised its position in Firefly Neuroscience by 393.3% during the third quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock worth $1,464,000 after acquiring an additional 401,085 shares during the period. Jane Street Group LLC acquired a new position in Firefly Neuroscience during the fourth quarter worth $53,000. Finally, BlackRock Inc. purchased a new position in Firefly Neuroscience during the second quarter valued at $226,000. Institutional investors and hedge funds own 4.96% of the company’s stock.

Firefly Neuroscience Company Profile

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.